Cargando…

Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan

BACKGROUND: Malaria rapid diagnostic tests (RDTs) are generally considered as point-of-care tests. However, most of the studies assessing the performance of malaria RDTs are conducted by research teams that are not representative of the classical end-users, who are typically unskilled in traditional...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Saorin, Nhem, Sina, Dourng, Dany, Ménard, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389415/
https://www.ncbi.nlm.nih.gov/pubmed/25889784
http://dx.doi.org/10.1186/s12936-015-0633-3
_version_ 1782365556754612224
author Kim, Saorin
Nhem, Sina
Dourng, Dany
Ménard, Didier
author_facet Kim, Saorin
Nhem, Sina
Dourng, Dany
Ménard, Didier
author_sort Kim, Saorin
collection PubMed
description BACKGROUND: Malaria rapid diagnostic tests (RDTs) are generally considered as point-of-care tests. However, most of the studies assessing the performance of malaria RDTs are conducted by research teams that are not representative of the classical end-users, who are typically unskilled in traditional laboratory techniques for diagnosing malaria. To evaluate the performance of a malaria RDT by end-users in a malaria-endemic area, a study protocol was designed and the VIKIA® Malaria Ag Pf/Pan test, previously evaluated in 2013, was re-evaluated by representative end-users. METHODS: Twenty end-users with four different profiles in seven communes in Kampot Province (Cambodia) were selected. A set of 20 calibrated aliquots, including negative samples, low positive samples (200 parasites/μL of Plasmodium falciparum and Plasmodium vivax) and high positive samples (2,000 parasites/μL of P. falciparum and P. vivax) was used. Testing was performed directly by the end-users without any practical training on the VIKIA® Malaria Ag Pf/Pan kit. RESULTS: All results obtained by the end-users were consistent with the expected results, except for the low positive (200 parasites/μL) P. vivax aliquot (35% of concordant results). No significant difference was observed between the different end-users. End-user interviews evaluating ease-of-use and ease-of-reading of the VIKIA® Malaria Ag Pf/Pan kit recorded 159 positive answers and only one negative answer. Out of 20 end-users, only one considered the test was not easy to perform with the support of the quick guide. CONCLUSIONS: The data presented in this study clearly demonstrate that the performance of the VIKIA® Malaria Ag Pf/Pan test when performed by traditional end-users in field conditions is similar to that obtained by a research team and that this RDT can be considered as a point-of-care tool/assay. Furthermore, the protocol designed for this study could be used systematically in parallel to conventional evaluation studies to determine the performance of malaria RDTs in field conditions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0633-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4389415
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43894152015-04-09 Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan Kim, Saorin Nhem, Sina Dourng, Dany Ménard, Didier Malar J Research BACKGROUND: Malaria rapid diagnostic tests (RDTs) are generally considered as point-of-care tests. However, most of the studies assessing the performance of malaria RDTs are conducted by research teams that are not representative of the classical end-users, who are typically unskilled in traditional laboratory techniques for diagnosing malaria. To evaluate the performance of a malaria RDT by end-users in a malaria-endemic area, a study protocol was designed and the VIKIA® Malaria Ag Pf/Pan test, previously evaluated in 2013, was re-evaluated by representative end-users. METHODS: Twenty end-users with four different profiles in seven communes in Kampot Province (Cambodia) were selected. A set of 20 calibrated aliquots, including negative samples, low positive samples (200 parasites/μL of Plasmodium falciparum and Plasmodium vivax) and high positive samples (2,000 parasites/μL of P. falciparum and P. vivax) was used. Testing was performed directly by the end-users without any practical training on the VIKIA® Malaria Ag Pf/Pan kit. RESULTS: All results obtained by the end-users were consistent with the expected results, except for the low positive (200 parasites/μL) P. vivax aliquot (35% of concordant results). No significant difference was observed between the different end-users. End-user interviews evaluating ease-of-use and ease-of-reading of the VIKIA® Malaria Ag Pf/Pan kit recorded 159 positive answers and only one negative answer. Out of 20 end-users, only one considered the test was not easy to perform with the support of the quick guide. CONCLUSIONS: The data presented in this study clearly demonstrate that the performance of the VIKIA® Malaria Ag Pf/Pan test when performed by traditional end-users in field conditions is similar to that obtained by a research team and that this RDT can be considered as a point-of-care tool/assay. Furthermore, the protocol designed for this study could be used systematically in parallel to conventional evaluation studies to determine the performance of malaria RDTs in field conditions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0633-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-14 /pmc/articles/PMC4389415/ /pubmed/25889784 http://dx.doi.org/10.1186/s12936-015-0633-3 Text en © Kim et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kim, Saorin
Nhem, Sina
Dourng, Dany
Ménard, Didier
Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title_full Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title_fullStr Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title_full_unstemmed Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title_short Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
title_sort malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the vikia® malaria ag pf/pan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389415/
https://www.ncbi.nlm.nih.gov/pubmed/25889784
http://dx.doi.org/10.1186/s12936-015-0633-3
work_keys_str_mv AT kimsaorin malariarapiddiagnostictestaspointofcareteststudyprotocolforevaluatingthevikiamalariaagpfpan
AT nhemsina malariarapiddiagnostictestaspointofcareteststudyprotocolforevaluatingthevikiamalariaagpfpan
AT dourngdany malariarapiddiagnostictestaspointofcareteststudyprotocolforevaluatingthevikiamalariaagpfpan
AT menarddidier malariarapiddiagnostictestaspointofcareteststudyprotocolforevaluatingthevikiamalariaagpfpan